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CC BY-NC-ND license (http://creativeAbstract Background/purpose: The aim of this study was to determine the molecular char-
acteristics of b-lactamase genes in extended-spectrum b-lactamase (ESBL)-producing Entero-
bacteriaceae isolates from Mongolia.
Methods: Fifty-six ESBL-producing Enterobacteriaceae isolates were collected, of which 46
were Escherichia coli, seven were Klebsiella pneumoniae, and three were K. oxytoca. Mini-
mum inhibitory concentrations for selected antibiotics were tested using the agar dilution
method, and the b-lactamase genes were determined using polymerase chain reaction com-
bined with sequencing. Pulsed-field gel electrophoresis (PFGE) was used for genotyping all iso-
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ESBL-producing Enterobacteriaceae in Mongolia 693Conjugation tests combined with plasmid digestion assays were used to determine whether
there was a horizontal spread in Mongolia.
Results: Among the 56 ESBL-producing isolates, 43 isolates (76.8%) were resistant to fluoroqui-
nolones, but all isolates were susceptible to carbapenems and amikacin. The polymerase chain
reaction sequencing results showed that the dominant CTX-M genotype was CTX-M-15 (19/46,
41.3%) in the ESBL-producing E. coli isolates. By contrast, CTX-M-14 and CTX-M-3 were the ma-
jor genotypes found in Klebsiella spp. Phylogenetic analysis revealed that 21 ESBL-producing E.
coli isolates belonged to group D (21/46, 45.6%), followed by group A (13/46, 28.3%), group B2
(11/46, 23.9%), and group B1 (1/46, 2.2%). Only four E. coli isolates (4/46, 8.7%) belonged to
the ST131 clone. PFGE showed that the ESBL-producing Enterobacteriaceae were genetically
unrelated. The conjugation assay showed that two plasmids harboring CTX-M-15 in E. coli iso-
lates were genetic unrelated, whereas seven plasmids harboring CTX-M-14 (5/7 and 2/7) and
four plasmids harboring CTX-M-55 (4/4) showed genetic relatedness, indicating the dissemina-
tion of resistance plasmids in this area.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Extended-spectrum b-lactamase (ESBL)-producing Enter-
obacteriaceae (EPE) are increasing rapidly all over the
world. At present, EPE are a growing threat to public
health, leading to serious infections and raising key thera-
peutic problems.1e5 ESBLs are among the Ambler Class A,
resistant to b-lactam antibiotics except cephamycins and
carbapenems, and are inhibited by clavulanic acid.1 In
addition, ESBLs are often located on plasmids harboring
resistance genes to other antimicrobial classes, resulting in
multidrug-resistant isolates and thus also facilitating their
transfer to different hosts.6,7
The first ESBLs have evolved from native b-lactamases
TEM and SHV by genetic mutation.8,9 However, since the
mid 2000s, a novel type of ESBL called CTX-M, from envi-
ronmental Kluyvera spp., has emerged worldwide.10 There
are currently > 150 different CTX-M-type ESBLs recognized
(http://www.lahey.org/Studies/) and grouped into six
major subgroups based on their amino acid identities,
named the CTX-M-1, -2, -8, -9, -25, and KLUC.11
CTX-M has been identified in several members of the
Enterobacteriaceae family, and especially in Escherichia
coli, which is the principal ESBL-producing member of the
Enterobacteriaceae.12,13 At present, CTX-M-15, derived
from CTX-M-3 by a substitution of Asp-240-Gly, which in-
creases its catalytic efficiency against ceftazidime,14 is
recognized as the most widely distributed CTX-M enzyme.15
In addition, the current pandemic spread of ESBL-producing
E. coli has been greatly facilitated by high-risk clones,
mainly the clonal group O25b:H4-B2-ST131.16,17 ST131
contains the CTX-M-15 enzyme, with high potential viru-
lence, and represents a major public health problem.16,17
Many reports have documented the emergence of
EPE.18e20 In our previous study, 18.3% of the clinical E. coli
isolated from patients in Mongolia are ESBL producers.21
However, the distribution of ESBL genotypes and plasmid
characteristics in EPE in Mongolia is still unclear. The aim of
this study was to investigate the molecular epidemiology
and genetic characteristics of clinical EPE isolates obtained
from two Mongolian hospitals.Materials and methods
Sampling and isolation of Enterobacteriaceae
The study protocols were approved by the National Ethics
Committee of Mongolia (20120925/6). Fifty-six nonconsec-
utive, nonduplicate clinical isolates were obtained from
inpatients hospitalized at National Central Hospital or Na-
tional Center for Maternal and Child Health in Mongolia.
These isolates were collected over a period of 5 months,
between February 2013 and June 2013. Presumptive
Enterobacteriaceae isolates were identified using standard
microbiological methods. The isolates were stored at 80C
in LuriaeBertani (LB) broth containing 20% glycerol (v/v)
until used.
Antimicrobial susceptibility testing and ESBL
confirmation
Antimicrobial susceptibilities were determined by the disk
diffusion method on MuellereHinton agar (Bio-Rad, Marne
la Coquette, France) according to the Clinical and Labora-
tory Standards Institute (CLSI) guidelines. ESBL-producing
isolates were screened using the double-disk synergy test in
accordance with CLSI guidelines.22 All ESBL-producing iso-
lates were tested for minimum inhibitory concentration
(MIC) of selected antimicrobial agents (from Sigma-Aldrich,
St. Louis, MO, USA; amikacin, cefepime, cefotaxime, cef-
tazidime, ciprofloxacin, ertapenem, levofloxacin; from USP
Standards, Rockville, MD, USA: cefoxitin, imipenem, mer-
openem) using the agar dilution method in accordance with
CLSI guidelines. E. coli ATCC 25922 and Klebsiella pneu-
moniae ATCC 700603 were used as quality control strains.
Molecular characterization of b-lactamases
The primers used in this study are described in Table 1.
Strains with a positive double-disk synergy test were
further studied using specific polymerase chain reaction
(PCR) amplification and sequencing of ESBL genes. DNA was
Table 1 Oligonucleotide primers used in this study
Primer Sequence (50e30) Refs
b-lactamase sequencing
CTX-M-M13U GGTTAAAAAATCACTGCGTC Jiang et al23
CTX-M-M13L TTGGTGACGATTTTAGCCGC
CTX-M-M9U ATGGTGACAAAGAGAGTGCA Jiang et al23
CTX-M-M9L CCCTTCGGCGATGATTCTC
TEM-2A(F) CCCCTATTTGTTTATTTTTCT Wu et al24
TEM-1B(R) GACAGTTACCAATGCTTAAT
SHV-3A(F) CCGGGTTATTCTTATTTGTC Wu et al24
SHV-2B(R) TAGCGTTGCCAGTGCTCGAT
Phylogenetic grouping
ChuA.1 GACGAACCAACGGTCAGGAT Clermont et al25
ChuA.2 TGCCGCCAGTACCAAAGACA
YjaA.1 TGAAGTGTCAGGAGACGCTG Clermont et al25
YjaA.2 ATGGAGAATGCGTTCCTCAAC
TspE4C2.1 GAGTAATGTCGGGGCATTCA Clermont et al25
TspE4C2.2 CGCGCCAACAAAGTATTACG
ST131 PCR screening
mdh36_forward GTTTAACGTTAACGCCGGT Jonhson et al26
mdh36_reverse GGTAACACCAGAGTGACCA
gyrB47_forward CGCGATAAGCGCGAC Jonhson et al26
gyrB47_reverse ACCGTCTTTTTCGGTGGAA
MLST typing
adk-F ATTCTGCTTGGCGCTCCGGG Tartof et al27
adk-R CCGTCAACTTTCGCGTATTT
fumC-F TCACAGGTCGCCAGCGCTTC Tartof et al27
fumC-R GTACGCAGCGAAAAAGATTC
icd-F ATGGAAAGTAAAGTAGTTGTTCCGGCACA Tartof et al27
icd-R GGACGCAGCAGGATCTGTT
purA-F CGCGCTGATGAAAGAGATGA Tartof et al27
purA-R CATACGGTAAGCCACGCAGA
gyrB-F TCGGCGACACGGATGACGGC Tartof et al27
gyrB-R ATCAGGCCTTCACGCGCATC
recA-F CGCATTCGCTTTACCCTGACC Tartof et al27
recA-R TCGTCGAAATCTACGGACCGGA
mdh-F ATGAAAGTCGCAGTCCTCGGCGCTGCTGGCGG Tartof et al27
mdh-R TTAACGAACTCCTGCCCCAGAGCGATATCTTTCTT
MLST Z multilocus sequence typing; PCR Z polymerase chain reaction.
694 C.-Y. Kao et al.extracted with the boiling method, and the ESBL-encoding
genes were identified using specific primers for the bla-
TEM, blaSHV, and blaCTX-M genes, previously
described,23,24 and followed by DNA sequencing. The DNA
sequences and deduced amino acid sequences were
compared with genes in the GenBank database (http://
www.ncbi.nlm.nih.gov/genbank/) or the b-lactamase clas-
sification system (http://www.lahey.org/studies/) to
confirm the subtypes of b-lactamase genes.
ESBL-producing E. coli phylogenetic grouping and
ST131 screening
ESBL-producing E. coli isolates were assigned to one of the
four main phylogenetic groups (A, B1, B2, and D), using a
combination of three DNA gene markers (chuA, yjaA, and
TSPE4-C2).25 To identify the ST131 clones, PCR for the
specific mdhA and gyrB genotype was used to screen for
ST131.26 Multilocus sequence typing (MLST) was further
carried out on suspected ST131 isolates according to theprotocol and primers described previously27 (http://mlst.
ucc.ie/).
Pulsed-field gel electrophoresis
Pulsed-field gel electrophore (PFGE) of XbaI-digested
genomic DNA samples of all isolates were carried out with a
CHEF Mapper XA apparatus (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA) according to the instruction manual.
Electrophoresis was performed for 27 hours at 14C with
pulse times ranging from 5 seconds to 35 seconds at 6 V/cm.
PFGE profiles were analyzed and compared using the Gel-
Compar II software, version 2.0 (Unimed Healthcare Inc.,
Houston, TX, USA).
Conjugation experiments and plasmid analysis
The liquid mating-out assay was carried out to transfer CTX-
M genes (CTX-M-14, CTX-M-15, and CTX-M-55) from ESBL-
ESBL-producing Enterobacteriaceae in Mongolia 695producing E. coli isolates to rifampicin-resistant E. coli
C600 as described previously.28 All testing isolates were
sensitive to rifampicin at the concentration of 256 mg/mL
except isolate 35. As a result, transconjugants were
selected on LB plates containing 256 mg/mL rifampicin
(Sigma-Aldrich) and 2 mg/mL cefotaxime. The plasmids
were extracted as described previously,29 followed by
electrophoresis in a 0.6% agarose gel at 50 V for 3 hours and
compared by coelectrophoresis with plasmids of known
sizes from Salmonella OU7526 to determine the plasmid
sizes.30 Plasmid DNA samples extracted from trans-
conjugants were digested with the endonuclease EcoRI
(New England Biolabs, Inc., Ipswich, MA, USA). The result-
ing fragments were electrophoretically separated in 0.8%
agarose gels.Results
Description of the bacterial isolates
During the study period, we collected 223 isolates, of which
56 (25.1%) from hospitalized patients were identified as
ESBL producers. Among these, 46 isolates were identified as
E. coli, seven were K. pneumoniae, and three were K.
oxytoca.
Antimicrobial susceptibility analyses showed that 39
ESBL-producing E. coli isolates (39/46, 84.8%) were resis-
tant to fluoroquinolones (including ciprofloxacin and levo-
floxacin). Only one K. pneumoniae isolate was resistant toTable 2 Phylogenic group, b-lactamase genes, and MIC ranges
Isolate Escherichia coli (n Z 46)a
Phylogenetic group A 13 (28.3) B1 1 (2.2) B2 11 (23.9)
CTX-M type
CTX-M-3 d d d
CTX-M-14 d d 6 (54.5)
CTX-M-15 8 (61.5) 1 (100) 2 (18.2)
CTX-M-14/15 1 (7.7) d d
CTX-M-22 d d d
CTX-M-14/22 d d d
CTX-M-24 d d d
CTX-M-27 d d 1 (9.1)
CTX-M-55 4 (30.8) d 2 (18.2)
Other b-lactamase
TEM-1 7 (53.8) d 9 (81.8)
SHV-1 d d d
MIC range (mg/mL)
CTX 32e>256 64 16e>256
CAZ 16e128 16 0.5e16
FOX 2e32 4 < 2e8
FEP 4e64 32 2e16
CIP 4e>32 32 4e32
LVX 4e64 16 4e32
a Four isolates belonged to the ST131 clone.
Data are presented as n (%) or range.
CAZZ ceftazidime; CIPZ ciprofloxacin; CTXZ cefotaxime; FEPZ c
spectrum b-lactamase; MIC Z minimum inhibitory concentration.fluoroquinolones (1/7, 14.6%), and all three K. oxytoca
isolates were resistant to fluoroquinolones. Importantly, all
these EPE isolates were susceptible to carbapenems
(including imipenem, meropenem, and ertapenem) and the
aminoglycoside (amikacin) generally used for EPE
treatment.Molecular analysis of b-lactamase genes
The nucleotide sequence analysis of the CTX-M, SHV,
and TEM genes are shown in Table 2. The dominant ge-
notype was CTX-M-15 (19/46, 41.3%) among the ESBL-
producing E. coli isolates, and the second most common
genotype was CTX-M-14 (14/46, 30.4%) (isolate 69 con-
tained CTX-M-14 and CTX-M-15; Table 2). In addition,
CTX-M-55 (8/46, 17.4%), CTX-M-24 (3/46, 6.5%), CTX-M-3
(2/46, 4.3%), and CTX-M-27 (1/46, 2.2%) were also found
in E. coli isolates. Among K. pneumoniae, three isolates
had CTX-M-3 (3/7, 42.9%), three had CTX-M-14 (3/7,
42.9%), and one had CTX-M-14/22 (1/7, 14.2%; Table 2).
Moreover, two K. oxytoca isolates contained CTX-M-3 (2/
3, 66.7%) and one contained CTX-M-22 (1/3, 33.3%;
Table 2).
Only TEM-1 and SHV-1 were identified in the TEM- and
SHV-producing isolates. Twenty-nine E. coli isolates con-
tained TEM-1 (29/46, 63.0%), and all K. oxytoca isolates
contained TEM-1 (3/3, 100%). Among K. pneumoniae, six
isolates (6/7, 85.7%) had both TEM-1 and SHV-1, and one
isolate had only SHV-1 (1/7, 14.3%; Table 2).among ESBL-producing isolates
Klebsiella
pneumonia
(n Z 7)
Klebsiella
oxytoca
(n Z 3)
D 21 (45.6) Total 46 (100) d d
2 (9.5) 2 (4.3) 3 (42.9) 2 (66.7)
7 (33.3) 13 (28.3) 3 (42.9) d
7 (33.3) 18 (39.1) d d
d 1 (2.2) d d
d d 1 (33.3)
d 1 (14.2) d
3 (14.3) 3 (6.5) d d
d 1 (2.2) d d
2 (9.6) 8 (17.4) d d
13 (61.9) 29 (63.0) 6 (85.7) 3 (100)
d 7 (100) d
16e>256 16e>256 8e256 128e>256
0.5e128 0.5e128 0.25e16 16
2e64 < 2e64 2e16 4
1e64 1e64 2e64 32e128
0.06e>32 0.06e>32 < 0.03e8 8e32
0.25e64 0.25e64 0.06e8 8e16
efepime; FOXZ cefoxitin; LVXZ levofloxacin; ESBLZ extended-
Figure 1. Dendrogram of PFGE patterns showing the genetic relatedness of ESBL-producing Enterobacteriaceae isolates. (A)
Escherichia coli, (B) Klebsiella pneumoniae, and (C) Klebsiella oxytoca. ESBLZ extended-spectrum b-lactamase; PFGEZ pulsed-
field gel electrophore.
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Phylogenetic analysis of the 46 E. coli isolates revealed four
main phylogenetic groups (A, B1, B2, and D). Table 2 showsFigure 2. Profiles of plasmids harboring CTX-M group genes. (A
conjugants. (B) EcoRI restriction digestion profiles of plasmids
Escherichia coli C600 is used as negative control; PZ parental isola
of 50 and 90 kb, respectively, and is used as plasmid size standard21 of the ESBL-producing E. coli isolates belonged to group
D (45.6%). Phylogenetic group A was the second most
common, present in 28.3% of the isolates (13/46). Phylo-
genetic group B2 was represented by 23.9% of the isolates) Plasmid sizes and numbers in parental isolates and trans-
harboring CTX-M group genes from transconjugants. N.C Z
tes; P.CZ Salmonella OU7526 contain two plasmids with sizes
control; TC Z transconjugants; M Z Marker, l-HindIII.
698 C.-Y. Kao et al.(11/46), and only one isolate (2.2%) belonged to group B1
(Table 2).
The current pandemic spread of ESBL-producing E. coli
has been greatly facilitated by high-risk clones, mainly the
clonal group O25b-ST131 producing the CTX-M-15
enzyme.16,17 All E. coli isolates were subjected to PCR
screening for the specific mdhA and gyrB genotype of
ST131, and further confirmed by multilocus sequence
typing. The results indicated only four E. coli isolates
belonged to the ST131 clone (4/46, 8.7%). Among them,
two isolates contained CTX-M-14 (isolates 14 and 35), one
contained CTX-M-15 (isolate 89), and one contained CTX-M-
27 (isolate 76).
PFGE
PFGE was performed on all confirmed ESBL-producing iso-
lates. Using a > 80% similarity cutoff point, PFGE analysis
showed genetic heterogeneity in the CTX-M-producing iso-
lates (Figure 1). Only four pairs of E. coli isolates (61 and
66; 19 and 29; 76 and 81; and 2 and 12) and three K.
pneumonia isolates (44, 47, and 59) showed genetic relat-
edness (Figure 1).
Resistance transfer and plasmid analysis
E. coli isolates with CTX-M-14, CTX-M-15, and CTX-M-55
were further analyzed with conjugation tests to deter-
mine whether there was a horizontal plasmid spread in
Mongolia. Transfer of ESBL enzyme by conjugation to E. coli
C600 was successful for 13 (33.3%; including 2 CTX-M-15, 6
CTX-M-14, 1 CTX-M-14/15, and 4 CTX-M-55 producing iso-
lates) of the 39 selected ESBL isolates (Figure 2). Trans-
conjugants harboring CTX-M-15 or CTX-M-55 showed higher
level resistance to cefotaxime compared to the trans-
conjugants harboring CTX-M-14 (Table 3). Moreover,
although all successful transconjugants showed resistanceTable 3 Antimicrobial susceptibility profiles of selected Escher
Isolate CTX-M
Parental isolates
CTX CAZ CIP
23 15 > 256 128 > 32
90 15 > 256 32 16
69 14/15 128 32 32
6 14 32 2 16
22 14 16 2 16
56 14 16 2 32
102 14 128 2 8
103 14 64 2 >32
104 14 32 2 >32
3 55 > 256 64 0.25
20 55 > 256 128 > 32
37 55 256 32 32
43 55 > 256 16 8
a MICs to CTX, CAZ, CIP, and LVX of E. coli C600 recipient strain w
respectively.
CTX Z cefotaxime; CAZ Z ceftazidime; CIP Z ciprofloxacin; LVX Zto cefotaxime, all were still sensitive to fluoroquinolones
(Table 3). Plasmid sizes present in parental isolates and
transconjugants were verified by Kado and Liu’s29 methods,
and the results revealed that all transconjugants contained
single plasmid with sizes ranging between 50 kb and 90 kb
(Figure 2A). Four CTX-M-14 transconjugants (220, 560, 1030,
and 1040) contained similar plasmid digestion patterns, and
this plasmid pattern was also found in a transconjugant of
isolate 69 harboring CTX-M-14/15 (Figure 2B). In addition,
CTX-M-14 containing a similar plasmid digestion pattern
was found in the transconjugants of isolates 6 and 102. All
successful transconjugants with CTX-M-55 (from isolates, 3,
20, 37, and 43) also showed similar plasmid digestion pat-
terns (Figure 2B). Two CTX-M-15 transconjugants were
shown to be genetically unrelated by plasmid digestion
patterns.
Discussion
In this study, we present the characteristics of 56 ESBL-
producing E. coli and Klebsiella spp. isolates from
Mongolia. The EPE isolates showed high resistance to fluo-
roquinolones, but not to carbapenems and the amino-
glycoside. CTX-M-15 was the dominant genotype in ESBL-
producing E. coli isolates, and CTX-M-14 and CTX-M-3
were the major genotypes among ESBL-producing Klebsi-
ella spp. isolates. In addition, plasmids containing the CTX-
M-14 or CTX-M-55 enzymes appear to be disseminated in
this area.
The CTX-M-15 genotype is reported to be the most
prevalent in all continents.31,32 The rapid emergence of
CTX-M-15-producing E. coli worldwide is attributed to the
dissemination of mobile genetic elements, as well as the
spread of specific clones, predominantly the international
clone ST131.16,17,33 In this study, the dominant ESBL geno-
type was CTX-M-15 (19/46, 41.3%) in ESBL-producing E. coli
isolates (Table 2). The second most common genotype isichia coli isolates and their transconjugants
Antibiotics (mg/mL)
Transconjugantsa
LVX CTX CAZ CIP LVX
64 128 32 < 0.03 0.06
32 256 64 < 0.03 0.06
32 32 2 < 0.03 0.06
16 32 4 < 0.03 0.06
8 16 2 < 0.03 0.06
8 16 1 < 0.03 0.06
16 32 4 < 0.03 0.06
16 8 1 < 0.03 0.06
6 8 1 0.06 0.12
0.5 128 16 < 0.03 0.06
32 128 32 < 0.03 0.06
16 64 32 < 0.03 0.06
4 64 16 < 0.03 0.06
ere < 0.03 mg/mL, 0.12 mg/mL, < 0.03 mg/mL, and 0.06 mg/mL,
levofloxacin; MIC Z minimum inhibitory concentration.
ESBL-producing Enterobacteriaceae in Mongolia 699CTX-M-14 (14/46, 30.4%). The prevalence of CTX-M geno-
types was similar to that reported in a previous study in
Korea, located close to Mongolia.34 However, the clonal
spread of the ST131 epidemic E. coli is not linked to ESBL-
producing E. coli in Mongolia. In addition, the results of
PFGE showed that the majority of strains were genetically
unrelated in Mongolia (Figure 1).
Previous studies showed that the phylogenetic group B2
was the most common in many countries, and group A and
group B1 were usually isolated as commensals.4,33 In
Mongolia, the prevalence of group D (21/46, 45.6%) and
group A (13/46, 28.3%) was dramatically higher than in
other countries.4,33 Whether the characteristics and viru-
lence of phylogenetic groups D and A of E. coli in Mongolia
are different from those in other countries is worth
evaluating.
The high similarity of plasmids encoding CTX-M-14 or
CTX-M-55 isolated from transconjugants strongly suggests
that plasmid transmission among clonally unrelated strains
of CTX-M-14 and CTX-M-55-producing E. coli might be tak-
ing place in Mongolia, whereas the diversity among plas-
mids encoding CTX-M-15 would rule out a common source of
these plasmids (Figure 2B). Importantly, similar RFLP
plasmid profiles were observed in the transconjugants of
isolate 90 (CTX-M-15 producer) and CTX-M-55 producers
(Figure 2B). CTX-M-55 is most closely related to CTX-M-15
with only a single amino acid substitution, Ala-77-Val,
raising the possibility that the conversion is between CTX-
M-55 and CTX-M-15 on the transferable plasmid. As a
result, the characterization and dissemination of similar
plasmid containing CTX-M-55 or CTX-M-15 in Mongolia is
thus worth investigating.
Previous studies indicate that E. coli uses different
mechanisms to provide resistance to fluoroquinolones;
however, mutations in the chromosomal genes (gyrA, gyrB,
parC, and parE) for topoisomerases are generally required
for higher-level fluoroquinolone resistance.35e38 In this
study, we found a remarkably high prevalence of
fluoroquinolone-resistant ESBL-producing E. coli (39/46,
84.8%; Table 2). The conjugation tests showed that all
transconjugants were resistant to cefotaxime but sensitive
to fluoroquinolones (Table 3). Moreover, isolates 3, 20, 37,
and 43 harbored homogenous CTX-M-55 containing plasmids
with different susceptibilities to fluoroquinolones
(Figure 2). Taken together, these results raised the possi-
bility that the fluoroquinolone-resistant determinants did
not coexist in the CTX-M producing plasmid. However, the
mechanisms leading to fluoroquinolone resistance in ESBL-
producing E. coli in Mongolia is still unclear and thus
worth studying.
In summary, CTX-M-15 is the most frequent ESBL pro-
duced by E. coli isolated from hospitalized patients in
Mongolia, followed by CTX-M-14 and CTX-M-55. Plasmids
encoding the CTX-M-14 or CTX-M-55 enzymes appear to be
very closely related, suggesting that they could share a
common origin.Conflicts interest
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